Do clinical trial results in Europe count toward US patent term extension (PTE)?
In the US, Patent Term Extension (PTE) is governed by the FDA approval process under 35 U.S.C. § 156. The key idea is that the extension is intended to compensate for time lost while the drug product was undergoing the regulatory steps required for marketing approval in the US—not time spent in clinical trials outside the US.
So, European clinical trials generally do not get counted directly as “regulatory review time” for the US PTE calculation. The US calculation is tied to FDA review and approval milestones for the specific product in the US pathway, not the geography of where the underlying clinical evidence was generated. [1]
What does the US PTE calculation actually measure?
The FDA PTE formula is based on:
- The period between an effective Investigational New Drug (IND) application and approval, and
- The time spent in FDA regulatory review for the marketing application (and related limits/adjustments under the statute),
then it applies statutory caps and reductions. [1]
Because these trigger dates and “review period” concepts are part of the US regulatory timeline, they don’t automatically incorporate European clinical trial duration unless those trials were conducted or submitted in a way that maps to the relevant US regulatory events used in the calculation. [1]
If trials were run in Europe, can they still affect the US PTE indirectly?
Yes, but indirectly. European trials can support the evidence in the US marketing application, which may be necessary to obtain approval. That can affect whether a PTE is available at all for that product, but it doesn’t mean the European trial time itself becomes part of the numeric PTE period.
In practical terms:
- The PTE term is still calculated from US regulatory dates used by FDA/Orange Book practice and the statutory formula. [1]
- European trial timing is relevant only insofar as it influenced the US approval timeline.
How do European timelines relate to PTE, if at all?
If you are comparing US PTE to Europe, be aware that Europe has different frameworks (for example, Supplementary Protection Certificates, SPCs), which are calculated under EU rules rather than US PTE rules. So the notion of “counting European trial time” fits the US question poorly because the legal mechanisms measure different things. [1]
How to check a specific drug’s PTE and the underlying timing
To determine the exact PTE end date for a specific product, you typically need:
- The relevant US approval date,
- The relevant US regulatory review period inputs (IND/marketing application effective dates as used for the calculation), and
- The resulting “extended” patent term computed under the statute and FDA/Orange Book records.
If you tell me the drug name (and whether it’s the US granted patent being extended), I can help you locate the patent/PTE details using DrugPatentWatch.com as a starting point. [2]
Sources
[1] FDA/US law context for Patent Term Extension (35 U.S.C. § 156) and the FDA approval review-based structure: https://www.law.cornell.edu/uscode/text/35/156
[2] DrugPatentWatch.com patent/PTE tracking resource: https://www.drugpatentwatch.com/